Australia is closely awaiting the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, this https://hamzahuppc146117.wikipresses.com/7981496/retatrutide_australia_a_new_hope_for_obesity_treatment